Fig. 1From: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinomaKaplan-Meier plot of progression-free survival (A) and overall survival (B) by baseline biomarker levels dichotomized at the medianBack to article page